LU93315I2 - Procédé de traitement de la sclérose multiple - daclizumab - Google Patents

Procédé de traitement de la sclérose multiple - daclizumab Download PDF

Info

Publication number
LU93315I2
LU93315I2 LU93315C LU93315C LU93315I2 LU 93315 I2 LU93315 I2 LU 93315I2 LU 93315 C LU93315 C LU 93315C LU 93315 C LU93315 C LU 93315C LU 93315 I2 LU93315 I2 LU 93315I2
Authority
LU
Luxembourg
Prior art keywords
daclizumab
multiple sclerosis
treating multiple
treating
sclerosis
Prior art date
Application number
LU93315C
Other languages
English (en)
Original Assignee
Us Gov Health & Human Serv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Gov Health & Human Serv filed Critical Us Gov Health & Human Serv
Publication of LU93315I2 publication Critical patent/LU93315I2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/0033—Features or image-related aspects of imaging apparatus classified in A61B5/00, e.g. for MRI, optical tomography or impedance tomography apparatus; arrangements of imaging apparatus in a room
    • A61B5/004—Features or image-related aspects of imaging apparatus classified in A61B5/00, e.g. for MRI, optical tomography or impedance tomography apparatus; arrangements of imaging apparatus in a room adapted for image acquisition of a particular organ or body part
    • A61B5/0042—Features or image-related aspects of imaging apparatus classified in A61B5/00, e.g. for MRI, optical tomography or impedance tomography apparatus; arrangements of imaging apparatus in a room adapted for image acquisition of a particular organ or body part for the brain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/05—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves 
    • A61B5/055—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves  involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/48—Other medical applications
    • A61B5/4848—Monitoring or testing the effects of treatment, e.g. of medication
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
LU93315C 2002-06-28 2016-11-17 Procédé de traitement de la sclérose multiple - daclizumab LU93315I2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US39302102P 2002-06-28 2002-06-28
PCT/US2002/038290 WO2004002500A1 (fr) 2002-06-28 2002-11-27 Procede de traitement de maladies auto-immunes au moyen d'interferon beta et de l'antagoniste du il-2r
PCT/US2003/020428 WO2004002421A2 (fr) 2002-06-28 2003-06-27 Procede de traitement de la sclerose en plaques

Publications (1)

Publication Number Publication Date
LU93315I2 true LU93315I2 (fr) 2017-01-26

Family

ID=30000962

Family Applications (1)

Application Number Title Priority Date Filing Date
LU93315C LU93315I2 (fr) 2002-06-28 2016-11-17 Procédé de traitement de la sclérose multiple - daclizumab

Country Status (15)

Country Link
US (11) US7575742B2 (fr)
EP (3) EP2314627B1 (fr)
JP (8) JP2005535636A (fr)
AU (3) AU2002368055B2 (fr)
CA (3) CA2490804C (fr)
CY (2) CY2016043I2 (fr)
DK (2) DK2314627T3 (fr)
ES (2) ES2474718T3 (fr)
HK (2) HK1074769A1 (fr)
HU (2) HUE036677T2 (fr)
IL (2) IL165973A (fr)
LU (1) LU93315I2 (fr)
PT (2) PT2314627T (fr)
SI (2) SI2314627T1 (fr)
WO (2) WO2004002500A1 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002303524B2 (en) * 2001-04-26 2008-03-06 Fallbrook Intellectual Property Company Llc Continuously variable transmission
AU2002368055B2 (en) 2002-06-28 2008-09-18 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of treating autoimmune diseases with interferon-beta and IL-2R antagonist
US20060134750A1 (en) * 2004-03-10 2006-06-22 Pepgen Corporation Method of treatment using interferon-tau
JP5192823B2 (ja) 2005-01-12 2013-05-08 バイオジェン・アイデック・エムエイ・インコーポレイテッド インターフェロン−βを送達するための方法
WO2006089066A1 (fr) * 2005-02-15 2006-08-24 Neuromolecular Pharmaceuticals, Inc. Polytherapie pour le traitement d'etats de demyelinisation
AU2008247815B2 (en) 2007-05-02 2012-09-06 Ambrx, Inc. Modified interferon beta polypeptides and their uses
RU2011111391A (ru) * 2008-08-28 2012-10-10 Эбботт Байотерапьютикс Корп. (Us) Способ лечения пациентов, страдающих рассеянным склерозом, антителами анти-il2r
JP2012505257A (ja) * 2008-10-13 2012-03-01 バイオヴィスタ，インコーポレイテッド 多発性硬化症治療のための組成物および方法
WO2010068923A2 (fr) * 2008-12-12 2010-06-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Agents inhibant sélectivement cd25 sur des cellules dendritiques ou des lymphocytes t et leur utilisation
CA2771335A1 (fr) * 2009-08-31 2011-03-03 Abbott Biotherapeutics Corp. Utilisation d'une population de cellules nk immunoregulatrices pour surveiller l'efficacite d'anticorps anti-il-2r chez des patients atteints d'une sclerose en plaques
WO2011127324A2 (fr) * 2010-04-08 2011-10-13 JN Biosciences, LLC Anticorps anti-cd122
WO2015089217A2 (fr) 2013-12-10 2015-06-18 Bionz, Llc Procédés de développement d'antagonistes peptidiques sélectifs
PT2665486T (pt) 2011-01-18 2020-03-30 Bioniz Llc Composições para modular a atividade das citocinas gama-c
US9809652B2 (en) 2011-08-08 2017-11-07 Abbvie Biotherapeutics Inc. Methods of treating progressive forms of multiple sclerosis comprising subcutaneously administering daclizumab
US10030058B2 (en) 2015-10-09 2018-07-24 Bioniz, Llc Modulating gamma-C-cytokine activity
WO2018027195A1 (fr) 2016-08-05 2018-02-08 Abbvie Biotherapeutics Inc. Compositions contenant des quantités réduites d'isoformes acides de daclizumab et procédés de préparation associés
DE102017104088A1 (de) * 2017-02-28 2018-08-30 L&O Hunting Group GmbH Integralschalldämpfer für einen Gewehrlauf

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4819150A (en) 1985-04-05 1989-04-04 Unisys Corporation Array for simulating computer functions for large computer systems
US5011684A (en) * 1985-09-05 1991-04-30 Beth Israel Hospital Association Lysing or blocking unwanted cells with IL-2 receptor-specific binding substance
US5336489A (en) 1985-09-05 1994-08-09 The Beth Israel Hospital Association Treatment of allograft rejection with IL-2 receptor-specific cytotoxins
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB2188941B (en) * 1986-04-14 1990-06-06 Bayer Ag Monoclonal antibodies recognizing human interleukin-2-receptor
US6051405A (en) * 1986-09-24 2000-04-18 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Constructs encoding recombinant antibody-toxin fusion proteins
US5013548A (en) 1987-09-08 1991-05-07 Duke University Production of antibodies to HIV
US5695927A (en) 1988-03-31 1997-12-09 The University Of Arizona, Department Of Internal Medicine, Section Of Hematology And Oncology Monoclonal antibodies specific for HIV and the hybridomas for production thereof
AU631545B2 (en) 1988-04-15 1992-12-03 Protein Design Labs, Inc. Il-2 receptor-specific chimeric antibodies
DE3815472A1 (de) * 1988-05-06 1989-11-16 Centre Regional De Transfusion Monoklonaler antikoerper und seine verwendung
US5152980A (en) 1988-05-19 1992-10-06 The Beth Israel Hospital Association Induction of tolerance to a foreign antigen IL-2 receptor-binding substances
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
ATE139258T1 (de) 1990-01-12 1996-06-15 Cell Genesys Inc Erzeugung xenogener antikörper
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
WO1992020791A1 (fr) 1990-07-10 1992-11-26 Cambridge Antibody Technology Limited Methode de production de chainons de paires de liaison specifique
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5620686A (en) 1990-09-28 1997-04-15 British Technology Group Limited Antigen-antibody conjugates
US5824549A (en) * 1990-10-09 1998-10-20 Chiron Corporation Transformed human T cell
FR2672291A1 (fr) 1991-01-31 1992-08-07 Inst Nat Sante Rech Med Composition d'anticorps diriges contre le recepteur de l'interleukine-2 humaine ou animale.
GB9115010D0 (en) 1991-07-11 1991-08-28 Wellcome Found Antibody
JPH05244982A (ja) * 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
AU3328493A (en) 1991-12-17 1993-07-19 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5571507A (en) 1992-02-25 1996-11-05 Seragen, Inc. Methods of treating diabetes
US5643756A (en) 1992-08-28 1997-07-01 The Public Health Research Institute Of The City Of New York, Inc. Fusion glycoproteins
DK0699077T3 (da) 1993-05-07 2002-01-21 Bio Merieux Inc Immunogele HIV-komplekser
CA2159366A1 (fr) 1993-08-27 1995-03-02 Michael R. Perry Systeme mecanique d'evacuation des gaz
US5635597A (en) 1994-05-27 1997-06-03 Affymax Technologies, N.V. Peptides that bind IL-2 receptors
ES2267100T5 (es) 1994-07-15 2011-04-08 The University Of Iowa Research Foundation Oligonucleótidos inmunomoduladores.
US6096728A (en) * 1996-02-09 2000-08-01 Amgen Inc. Composition and method for treating inflammatory diseases
US6013256A (en) * 1996-09-24 2000-01-11 Protein Design Labs, Inc. Method of preventing acute rejection following solid organ transplantation
US6833135B1 (en) * 1997-08-06 2004-12-21 Laboratorio Medinfar Produtos Farmaceuticos, Lda. DNA integration into “Mycobacterium spp.” genome by trans-complementation using a site-specific integration system
WO2000025816A1 (fr) 1998-10-30 2000-05-11 The University Of Miami Traitement de l'hepatite c par administration d'un anticorps monoclonal anti recepteur de il-2 et d'un compose antiviral
US6346247B1 (en) 1999-10-28 2002-02-12 Promega Corporation Prevention and treatment of autoimmune disease with luminally administered polyclonal antibodies
EP1321153A4 (fr) 2000-04-25 2005-02-16 Tomoaki Hoshino Substances medicamenteuses destinees a la pneumonie interstitielle, procede de construction d'un modele animal de cette maladie et procede de criblage dans lequel on utilise ce dernier
KR100975042B1 (ko) * 2001-04-06 2010-08-11 더 유니버시티 오브 브리스톨 스테로이드-내성 환자에서의 ｃｄ25 결합 분자의 용도
AU2002368055B2 (en) 2002-06-28 2008-09-18 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of treating autoimmune diseases with interferon-beta and IL-2R antagonist
WO2004003156A2 (fr) 2002-07-01 2004-01-08 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Le l-21, regulateur de la production d'immunoglobine

Also Published As

Publication number Publication date
PT2314627T (pt) 2017-08-29
HK1074769A1 (en) 2005-11-25
US20040109859A1 (en) 2004-06-10
HUS1600050I1 (hu) 2017-06-28
US20150010477A1 (en) 2015-01-08
WO2004002421A3 (fr) 2004-09-02
US20090175823A1 (en) 2009-07-09
JP2006508039A (ja) 2006-03-09
US20080038275A1 (en) 2008-02-14
DK2314627T3 (en) 2017-10-23
CY2016043I1 (el) 2017-04-05
US20170190779A1 (en) 2017-07-06
AU2002368055A1 (en) 2004-01-19
ES2474718T3 (es) 2014-07-09
US8636997B2 (en) 2014-01-28
US7258859B2 (en) 2007-08-21
AU2003247813C1 (en) 2010-07-22
EP1539200B1 (fr) 2014-05-28
AU2002368055B2 (en) 2008-09-18
JP2014221813A (ja) 2014-11-27
AU2008212004B2 (en) 2010-10-21
JP2010132660A (ja) 2010-06-17
IL165973A0 (en) 2006-01-15
US20150337044A1 (en) 2015-11-26
AU2008212004A1 (en) 2008-09-25
JP2013032372A (ja) 2013-02-14
SI1539200T1 (sl) 2014-09-30
SI2314627T1 (sl) 2017-10-30
IL241920A0 (en) 2015-11-30
EP2314627B1 (fr) 2017-07-26
HUE036677T2 (hu) 2018-07-30
DK1539200T3 (da) 2014-06-30
PT1539200E (pt) 2014-08-25
US8298525B2 (en) 2012-10-30
EP2314627A2 (fr) 2011-04-27
US20180237532A1 (en) 2018-08-23
US20190002575A1 (en) 2019-01-03
US20130095069A1 (en) 2013-04-18
CA2844639A1 (fr) 2004-01-08
US20130017152A1 (en) 2013-01-17
JP2005535636A (ja) 2005-11-24
CA2490186A1 (fr) 2004-01-08
JP2016145220A (ja) 2016-08-12
EP3269377A1 (fr) 2018-01-17
CA2490804C (fr) 2016-12-06
US20050249704A1 (en) 2005-11-10
JP2011157378A (ja) 2011-08-18
JP2013139478A (ja) 2013-07-18
EP2314627A3 (fr) 2011-05-11
AU2003247813B2 (en) 2008-06-05
HK1249850A1 (zh) 2018-11-16
WO2004002421A2 (fr) 2004-01-08
US8454965B2 (en) 2013-06-04
CA2490186C (fr) 2014-04-15
CA2490804A1 (fr) 2004-01-08
CY2016043I2 (el) 2017-04-05
JP5905534B2 (ja) 2016-04-20
WO2004002500A1 (fr) 2004-01-08
EP1539200A4 (fr) 2007-11-07
CY1119389T1 (el) 2018-02-14
IL165973A (en) 2015-10-29
US7575742B2 (en) 2009-08-18
EP1539200A2 (fr) 2005-06-15
ES2637011T3 (es) 2017-10-10
AU2003247813A1 (en) 2004-01-19

Similar Documents

Publication Publication Date Title
LU93315I2 (fr) Procédé de traitement de la sclérose multiple - daclizumab
IL175818A0 (en) Method for treating adamts-5- associated disease
PL1655036T3 (pl) Sposób leczenia chorób onkologicznych
NO20030241D0 (no) Fremgangsmåte for behandling av multiple brönnintervaller
AU2003303198A8 (en) Method for treating amyloid disease
DK1997512T3 (da) Fremgangsmåder til behandling af TWEAK-relaterede tilstande
FR2814945B1 (fr) Procede de traitement de la canitie
HK1102831A1 (en) Process for treating animal skins
FI20020942A0 (fi) Menetelmä tärkkelyksen käsittelemiseksi
BR0312187B1 (pt) método para o tratamento de sementes
FI20030497A0 (fi) Menetelmä jätehapon käsittelemiseksi
FI20030735A0 (fi) Menetelmä ja laite veden käsittelemiseksi
FI20030736A0 (fi) Menetelmä ja laite veden käsittelemiseksi
FI20020849A0 (fi) Menetelmä tekstiilin käsittelyyn
FR2853309B1 (fr) Procede et installation de traitement de dejections animales
DE50311871D1 (de) System zum herstellen von getrieben
ITTO20020081A0 (it) Apparato e metodo per la produzione di filato.
ITMI20020809A1 (it) Metodo per la selezione di composti utili nel trattamento della coreadi huntington
GB0304215D0 (en) Method for treating waste
ITMI20031247A1 (it) Processo per la purificazione di gabapentina
ITMI20032456A1 (it) Processo per la purificazione di gabapentina
FI20021478A (fi) Menetelmä kuitupuun käsittelemiseksi
FR2857154B1 (fr) Procede de traitement des surfaces de semiconducteurs
FR2836689B1 (fr) Procede de cementation de pieces
FR2864076B1 (fr) Procede de fluorodesazotation